Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is There Still Room for Growth for These 2 Coronavirus Stocks?

By Adria Cimino - Dec 22, 2020 at 6:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They are at a critical point. What happens next could push them higher, or result in a big loss.

Is it a good idea to keep betting on a winner? That question may have crossed our minds as we look at Novavax ( NVAX -0.60% ) and Vaxart ( VXRT 3.31% ). Shares of these coronavirus vaccine developers soared more than 3,000% and 2,000%, respectively, this year. That makes them the top two performers in the U.S. stock market this year -- all industries and market capitalizations included.

It's tempting to buy or hold these shares because they have momentum. Their coronavirus vaccine programs are on investors' radar screens. And these programs have made progress. This fall, Novavax's vaccine candidate entered phase 3 trials, and Vaxart's entered phase 1. But there's also reason to be wary of stocks that have appreciated so much. Potential positive news may already be priced in at the current share price. So, should we be worried about investing in Novavax and Vaxart at this point? Or should we be more confident than ever? Let's take a closer look.

A researcher's gloved hands hold several $100 bills.

Image source: Getty Images.


Novavax entered the vaccine race this spring, around the same time as other leaders such as Moderna and Pfizer. Operation Warp Speed, the government's effort to shepherd a vaccine to market by January, offered Novavax $1.6 billion in early July. At the time, that was the initiative's biggest award to a company yet.

Over the past several months, Novavax not only continued vaccine development but also worked on capacity. The biotech company is prepared to produce more than 2 billion doses annually by mid-2021. That's more than Moderna and Pfizer. In fact, Novavax's capacity is only second to that of AstraZeneca ( AZN 0.68% ). This British rival aims to produce about three billion doses.

As for development, Novavax expects to generate interim phase 3 data (a program with more than 15,000 enrollments) by early first quarter of 2021. If the outcome of phase 3 clinical trials is positive, the company will request emergency authorizations in various countries. Novavax will also continue phase 3 studies to support full approval later in the year.

In 2021, actual product revenue and market share will determine whether Novavax's gains will continue. So far, trial results have been encouraging. And the company has garnered orders for at least 286 million doses of the vaccine globally. Those are reasons to be optimistic.


Vaxart isn't a leader in the vaccine race from a timeline perspective. The company recently completed dosing its first human subject. And it expects initial data from that trial in the coming weeks. If all goes smoothly and Vaxart follows in the footsteps of its larger, more advanced rivals, the company could apply for emergency use in the second half of 2021.

Why is there so much excitement for a vaccine that's, at best, months behind rivals? It has to do with vaccine delivery. Vaxart's product is an orally administered tablet that's stable at room temperature. In other words, it makes it easier to administer, transport, and store millions of doses. And that's a clear advantage over traditional vaccines. Pfizer's recently authorized vaccine, for example, requires ultra-low temperatures that will make widespread use a challenge.

Since Vaxart's program still is in very early human testing, I expect the next catalyst to be trial data reports. We still don't know if the company's technology is safe and effective clinically. If early trial results are strong, it's very likely the stock will appreciate further. However, a failure at this stage could crush the shares -- potentially sending them back to their less-than-$1 levels of 2019.

What does this mean for investors?

Novavax and Vaxart are unlikely to surge as much in 2021 as they did in 2020. There was a lot of excitement around the coronavirus vaccine development earlier this year. Investors placed big bets on potential winners, yet without much information whether their programs would be successful. Some of that excitement has since waned. Competition has multiplied, and investors are now looking for more concrete elements, such as how much revenue companies could potentially generate. In other words, their success now depends on the outcome of their respective clinical trials. 

Still, the coronavirus vaccine story of Novavax and Vaxart isn't over. Positive clinical trial data and potential regulatory authorizations mean there is room for further gains, while a failure could result in a big climb-down in share prices. Investors in these biotech stocks should keep a close eye on every news at this critical stage.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$181.75 (-0.60%) $-1.10
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$55.13 (0.68%) $0.37
Pfizer Inc. Stock Quote
Pfizer Inc.
$51.40 (-0.62%) $0.32
Moderna, Inc. Stock Quote
Moderna, Inc.
$283.40 (0.37%) $1.05
Vaxart, Inc. Stock Quote
Vaxart, Inc.
$6.56 (3.31%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.